Abstract: Currently, therapeutic methods for advanced and recurrent cervical cancer patients are limited and unsatisfactory. Immunotherapy is a promising approach for cancer treatment. However, its investigation and application in cervical cancer remain slow. Although pembrolizumab is a remarkable milestone as the first anti-PD-1 mAb approved by the FDA for treating cervical cancer, it shows relatively low response rate. It is noticed that multiple novel immune checkpoints have emerged in recent years, such as CTLA-4, TIGIT, LAG-3, TIM-3, and A2AR. Accumulated studies have suggested that strategies combining the PD-1/PD-L1 inhibitors and different immunotherapies or biotherapies could enhance the antitumor efficacy in human cancers. In this review article, we provide an overview of anti-PD-1/PD-L1-based immunotherapy in cervical cancer treatment. We further summarize the developmental strategies of different immunotherapies or biotherapies combined with PD-1/PD-L1 blockade for treating cervical cancer. We also discuss how these new combined therapies increase the therapeutic benefit gained from experimental evidence in cervical cancer.

Keywords: cervical cancer, immunotherapy, PD-1/PD-L1, combinatorial strategy, mechanism, clinical practice


中文翻译：

---

不同免疫治疗方法联合 PD-1/PD-L1 阻断治疗宫颈癌的新兴治疗策略

摘要：目前，晚期和复发性宫颈癌患者的治疗方法有限且不能令人满意。免疫疗法是一种很有前途的癌症治疗方法。然而，其在宫颈癌中的研究和应用仍然缓慢。虽然派姆单抗作为 FDA 批准用于治疗宫颈癌的首个抗 PD-1 mAb 是一个显着的里程碑，但它的反应率相对较低。值得注意的是，近年来出现了多个新的免疫检查点，如 CTLA-4、TIGIT、LAG-3、TIM-3 和 A2AR。积累的研究表明，将 PD-1/PD-L1 抑制剂与不同的免疫疗法或生物疗法相结合的策略可以增强人类癌症的抗肿瘤功效。在这篇综述文章中，我们概述了基于抗 PD-1/PD-L1 的免疫疗法在宫颈癌治疗中的应用。我们进一步总结了不同免疫疗法或生物疗法联合PD-1/PD-L1阻断治疗宫颈癌的发展策略。我们还讨论了这些新的联合疗法如何增加从宫颈癌的实验证据中获得的治疗益处。

关键词：宫颈癌，免疫治疗，PD-1/PD-L1，组合策略，机制，临床实践